Selective HDAC Inhibitors via Isoform Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current histone deacetylase inhibitors, such as SAHA and Romidepsin, have strong toxic side effects and limited selectivity, leading to cytotoxicity in normal cells and reduced efficacy in tumor treatment due to non-specific inhibition of HDAC pathways.
Innovation Solution
Development of novel 4-arylamino quinazoline hydroxamic acid compounds with optimized enzyme surface recognition and linking regions to create selective histone deacetylase inhibitors with improved pharmacokinetic characteristics and reduced impact on normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic drugs are used to block cell division, then tumor cells are killed, but normal cells are also damaged causing cytotoxicity
Solution Approach 1:
The patent segments the HDAC inhibitor class into multiple isoform-specific inhibitors (HDAC1, HDAC2, HDAC3, etc.), each targeting specific HDAC isoforms expressed in tumor cells versus normal cells. This segmentation allows selective inhibition of tumor-specific HDAC isoforms while sparing normal cells that rely on different isoforms, thereby reducing cytotoxicity while maintaining anti-tumor efficacy
Solution Approach 2:
The patent applies local quality by designing inhibitors with specific molecular structures that selectively bind to particular HDAC isoforms based on their unique active site characteristics. Each inhibitor has tailored chemical groups (e.g., hydroxamic acid, cyclic peptide, benzamide structures) that match the local structural features of specific HDAC isoforms, enabling selective inhibition in tumor cells without affecting normal cells
2Reliability
If non-selective HDAC inhibitors are used to inhibit HDAC pathways, then anti-tumor activity is achieved, but selectivity is reduced leading to reduced efficacy
Solution Approach 1:
The patent changes the molecular parameters of HDAC inhibitors by modifying chemical structure, binding affinity, and isoform specificity. By adjusting parameters such as the inhibitor's chemical groups, linker regions, and hydrophobic interactions, the patent creates a series of inhibitors with varying selectivity profiles for different HDAC isoforms, thereby achieving both anti-tumor activity and selectivity
Solution Approach 2:
The patent employs feedback mechanisms in the drug design process by using structure-activity relationship (SAR) studies and molecular modeling to iteratively optimize inhibitor selectivity. Experimental data on isoform-specific inhibition feeds back into structural modifications, creating a cycle of optimization that enhances both anti-tumor efficacy and selectivity for specific HDAC isoforms
Data Source
AI summary
A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.In Formula I, the variables are as described herein.